Day Zero Diagnostics
Day Zero Diagnostics is a Boston-based company pioneering infectious disease diagnostics using whole-genome sequencing and machine learning. Their mission is to revolutionize diagnosis and treatment of infectious diseases by providing rapid, comprehensive organism identification and antimicrobial resistance profiling without the need for culture, thereby enabling precision medicine and better outbreak management.
Industries
Nr. of Employees
medium (51-250)
Day Zero Diagnostics
250 Arsenal Place, Suite 320, Watertown, MA 02472
Products
Sample preparation method for direct-from-blood pathogen sequencing
A laboratory method to enrich and recover pathogen genomes directly from blood samples to enable whole-genome sequencing without prior culture.
Computational platform for AMR prediction from whole-genome data
A software platform that analyzes pathogen whole-genome sequences and returns predicted antimicrobial susceptibility profiles using machine learning models trained on large genome–phenotype datasets.
Sample preparation method for direct-from-blood pathogen sequencing
A laboratory method to enrich and recover pathogen genomes directly from blood samples to enable whole-genome sequencing without prior culture.
Computational platform for AMR prediction from whole-genome data
A software platform that analyzes pathogen whole-genome sequences and returns predicted antimicrobial susceptibility profiles using machine learning models trained on large genome–phenotype datasets.
Services
Laboratory and computational service that performs whole-genome sequencing and automated analysis to determine pathogen relatedness for suspected healthcare-associated infection outbreaks, with rapid turnaround intended to inform infection control decisions.
Computational service that uses whole-genome sequencing inputs and machine learning models to predict antimicrobial resistance and susceptibility profiles for clinical pathogens.
Laboratory and computational service that performs whole-genome sequencing and automated analysis to determine pathogen relatedness for suspected healthcare-associated infection outbreaks, with rapid turnaround intended to inform infection control decisions.
Computational service that uses whole-genome sequencing inputs and machine learning models to predict antimicrobial resistance and susceptibility profiles for clinical pathogens.
Expertise Areas
- Infectious disease genomics
- Antimicrobial resistance prediction
- Outbreak detection and genomic epidemiology
- Sample preparation for direct-from-sample sequencing
Key Technologies
- Whole-genome sequencing (WGS)
- Long-read sequencing
- Hybrid genome assembly (short + long reads)
- K-mer based genomic comparison algorithms
News & Updates
Day Zero Diagnostics presented three presentations at the 2024 ASM Microbe conference, demonstrating their machine learning platform Keynome® for rapid bacterial genome analysis and antimicrobial resistance prediction.
Research on plasmid-mediated antibiotic resistance in E. coli strains with high quinolone resistance was highlighted, supported by a $8.2 million award from CARB-X.
Day Zero Diagnostics received an $8.2 million award in optional stage funding from CARB-X to develop rapid genomic analysis algorithms for hospital infection outbreak detection.
Research on two E. coli strains with high resistance to quinolones revealed novel plasmid-mediated resistance mechanisms using nanopore sequencing and computational analysis.
Discussion on the importance of sequencing-based diagnostics in combating infectious diseases.
Overview of Day Zero Diagnostics' mission to address antibiotic resistance through genomics and machine learning.
Day Zero Diagnostics presented three presentations at the 2024 ASM Microbe conference, demonstrating their machine learning platform Keynome® for rapid bacterial genome analysis and antimicrobial resistance prediction.
Research on plasmid-mediated antibiotic resistance in E. coli strains with high quinolone resistance was highlighted, supported by a $8.2 million award from CARB-X.
Day Zero Diagnostics received an $8.2 million award in optional stage funding from CARB-X to develop rapid genomic analysis algorithms for hospital infection outbreak detection.
Research on two E. coli strains with high resistance to quinolones revealed novel plasmid-mediated resistance mechanisms using nanopore sequencing and computational analysis.
Discussion on the importance of sequencing-based diagnostics in combating infectious diseases.
Overview of Day Zero Diagnostics' mission to address antibiotic resistance through genomics and machine learning.